Targeting Gene Regulation in Disease
To find innovative solutions for diseases of abberant gene control by advancing the science of RNA and chromatin regulation, developing new technological platforms, and discovering early stage therapeutics.
To build a collaborative therapeutic center dedicated to excellence in studying and drugging gene regulation.
what’s trending: CENTER NEWS AND INSIGHTS
recent media & publications
Group Leader, Dr. Calla Olson’s paper on the development of a selective CDK7 inhibitor was published in Cell Chemical Biology. Collaborators from the Nathanael Gray Lab at Dana-Farber Cancer Institute and Charles Lin Lab at Baylor College of Medicine are among contributors.
pilot project applicants awarded!
Faculty members Dr. Stephen Mack and Joanna Yi applied for and were awarded funds from the first round of THINC translational seed awards! Their project titled “Degrading C11ORF95-RELA for therapeutic benefit in Ependymoma” will focus on advancing therapeutic efforts surrounding C11ORF95-RELA, and to develop a framework for advancement of other lead candidates in other pediatric malignancies.
upcoming events and deadlines
September 6, 2019: Application deadline for pilot projects *Details forthcoming
September 20, 2019: RNA and Chromatin Group talks resume!
To achieve our goal of translating fundamental discoveries in gene regulation into therapeutics, we will:
Align chemical biology, genomics, and computational biology for rigorous and focused therapeutic development
Recruit talented interdisciplinary scientists to rapidly discover new medicines
Bridge biological and chemical technology developments with the expertise of scientist and physicians at Baylor College of Medicine to impact diseases of altered gene control